Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094098 | 0.94 | KDM4E (0.37) | KDM4ETP53GAACNR1CNR2 | |
| SCHEMBL16757426 | 0.93 | KDM4E (0.36) | KDM4ETP53GAACNR1CNR2 | |
| SCHEMBL1109024 | 0.92 | CNR1 (0.37) | KDM4ETP53GAACNR1CNR2 | |
| SCHEMBL16757059 | 0.92 | CNR1 (0.44) | KDM4ETP53GAACNR1CNR2 | |
| SCHEMBL18352659 | 0.92 | CNR1 (0.37) | TP53GAACNR1CNR2MEN1 | |
| SCHEMBL16771542 | 0.91 | KDM4E (0.35) | KDM4ETP53GAACNR1CNR2 | |
| SCHEMBL16757127 | 0.89 | SLC22A12 (0.36) | KDM4ETP53GAACNR1CNR2 | |
| SCHEMBL33372518 | 0.87 | KDM4E (0.37) | KDM4ETP53GAACNR1CNR2 | |
| SCHEMBL16771639 | 0.86 | MAPT (0.38) | KDM4EGAACNR1CNR2MEN1 | |
| SCHEMBL13452404 | 0.86 | MEN1 (0.41) | KDM4EGAAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12427159-B2 | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3541373-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3541373-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3389654-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3389654-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20220305035-A1 | HYDROXYPYRROLIDINE-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2022-09-29 | — | — | US | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3983414-A1 | HYDROXYPYRROLIDINE-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | Merck Sharp & Dohme Corp. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| EP-2385938-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | KDM4E 4039/4885TP53 3397/4885GAA 1532/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | KDM4E 1408/4885TP53 1710/4885GAA 2829/4885 |
| US-12427159-B2 | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels | TRPV1, SCN1A, SCN7A | KDM4E 2033/4885TP53 4697/4885GAA 3905/4885 |
| US-20220305035-A1 | HYDROXYPYRROLIDINE-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | TRPV1, SCN1A, SCN7A | KDM4E 2033/4885TP53 4697/4885GAA 3905/4885 |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | KDM4E 1329/4885TP53 1416/4885GAA 1697/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | KDM4E 4039/4885TP53 3397/4885GAA 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.